Triple-Negative Breast Cancer (TNBC) Recruiting Phase 3 Trials for Paclitaxel (DB01229)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04085276Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentTreatment
NCT03125902A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)Treatment
NCT03197935A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerTreatment
NCT03002103A Trial Evaluating the Efficacy and Safety of EndoTAGĀ®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast CancerTreatment